Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Operating activities
Net loss	$ (87,467)	$ (106,231)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,800	3,551
Accretion of discount on marketable securities	(2,149)	(5,483)
Stock-based compensation	10,801	12,227
Non-cash lease expenses	2,841	2,482
Unrealized gain on equity securities	0	(8,487)
Non-cash interest expense on deferred royalty obligation	18,991	14,470
Other	303	430
Changes in operating assets and liabilities:
Accounts receivable	617	29,128
Prepaid expenses and other assets	6,421	(2,084)
Accounts payable	(5,726)	(3,292)
Accrued compensation	(1,141)	(4,746)
Accrued expenses and other liabilities	7,112	(5,383)
Deferred revenue	(63,449)	21,180
Change in operating lease liability	(3,561)	(3,048)
Net cash used in operating activities	(112,607)	(55,286)
Investing activities
Purchases of marketable securities	(170,973)	(292,332)
Maturities of marketable securities	135,750	265,313
Sales of marketable securities	22,805	11,951
Purchases of equipment and leasehold improvements	(1,260)	(1,202)
Net cash used in investing activities	(13,678)	(16,270)
Financing activities
Proceeds from sales of common stock, net of issuance costs	0	71,527
Proceeds from sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA)	0	25,000
Payment of debt	0	(4,083)
Proceeds from exercise of common stock options	0	117
Taxes paid related to net shares settlement of restricted stock units	(240)	(411)
Proceeds from employee stock purchase plan	246	911
Net cash provided by financing activities	6	93,061
Net (decrease) increase in cash, cash equivalents and restricted cash	(126,279)	21,505
Cash, cash equivalents and restricted cash at beginning of period	191,162	70,140
Cash, cash equivalents and restricted cash at end of period	64,883	91,645
Supplemental disclosure of cash flow information:
Cash paid for interest	0	63
Income tax paid	11	15,164
Supplemental disclosure of non-cash investing and financing information:
Purchases of equipment included in accounts payable and accrued expense	23	123
Financing component associated with program fees	2,008	3,918
Premium on common stock issued to Ipsen Biopharma, Inc. (USA)	$ 0	$ 429